Bachem's peptide franchise led while the CDMO and injectables layer softened, with Hikma the weakest on continued generics pressure.

The session favored the peptide-manufacturing chokepoint. The Bachem ADR (BCHMY) rose 4.8% to $9.78 on the peptides-oligos line — the outsourced synthesis capacity behind the GLP-1 wave. It was a modest gain on a thinly traded ADR with no single company headline on the day, so read it as the market paying up for the one CDMO node whose order book is effectively full: Bachem has said its 2026 slate is booked, with its Building K capacity ramping into the second half. It maps to the "TSMC of peptides" framing — the fill-finish-adjacent bottleneck that the obesity-drug buildout has to route through.

The laggard was the Hikma ADR (HKMPY), down 4.3% to $41.31 on the API-reshoring and sterile-injectables-shortages chokepoints. The move extends a multi-week de-rate that has run alongside cuts to 2026 EPS estimates; the generic-injectables franchise sits on genuinely scarce sterile-fill capacity, but it is being priced on pricing pressure rather than scarcity right now.

The broader tape leaned soft across the outsourced-manufacturing layer. Maravai (MRVI) fell 3.3% to $6.95 on the peptides-oligos chokepoint, the Lonza ADR (LZAGY) eased 3.0% to $66.41 across fill-finish and CDMO capacity, and the WuXi AppTec ADR (WUXAY) dropped 2.8% to $24.60 on the API-reshoring and CDMO lines. The tools names were heavier too — Mettler-Toledo (MTD) off 2.7% and Repligen (RGEN) down 2.1% on bioprocessing. The read is a split within the vertical: the capacity-constrained peptide node bid, while the broader CDMO and China-exposed names carried the day's weakness, the WuXi lines still shadowed by BIOSECURE-Act risk.

The calendar sets up the fall. CPHI Worldwide runs Oct 6–8 in Milan, the industry's largest supply-chain gathering and a read on CDMO capacity and API sourcing. Company prints follow — West Pharmaceutical's Q3 on Oct 22 and Charles River's Q3 around Nov 5 — bracketing the packaging-components and preclinical-services chokepoints. The policy swing factor is dated: the OMB's initial BIOSECURE "companies of concern" list is due Dec 18, the designation that would formalize the reshoring pressure the WuXi names are already discounting, and Stevanato's (STVN) US and Italian ready-to-use cartridge lines are targeted for commercial output around the turn of the year — the drug-packaging capacity the injectables shortage needs.